This pattern coincided with the upregulation of key markers associated with cancer stemness (CD133, CD44) and metastasis/invasion (MMP7, CD74) (Fig. 1a and Supplementary Fig. 1c, d), highlighting FXYD5 as a potential driver of malignant progression. Here, CD44 is linked to cancer.